JP2023543993A - 遺伝性出血性毛細血管拡張症の治療における使用のためのアロステリックａｋｔ阻害剤 - Google Patents

遺伝性出血性毛細血管拡張症の治療における使用のためのアロステリックａｋｔ阻害剤 Download PDF

Info

Publication number
JP2023543993A
JP2023543993A JP2023519016A JP2023519016A JP2023543993A JP 2023543993 A JP2023543993 A JP 2023543993A JP 2023519016 A JP2023519016 A JP 2023519016A JP 2023519016 A JP2023519016 A JP 2023519016A JP 2023543993 A JP2023543993 A JP 2023543993A
Authority
JP
Japan
Prior art keywords
compound
use according
hht
subject
telangiectasia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023519016A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023543993A5 (https=
Inventor
ダミアン ピカール
ピエール サン－メザール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaderis Therapeutics AG
Original Assignee
Vaderis Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaderis Therapeutics AG filed Critical Vaderis Therapeutics AG
Publication of JP2023543993A publication Critical patent/JP2023543993A/ja
Publication of JP2023543993A5 publication Critical patent/JP2023543993A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2023519016A 2020-09-30 2021-09-29 遺伝性出血性毛細血管拡張症の治療における使用のためのアロステリックａｋｔ阻害剤 Pending JP2023543993A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2015536.2 2020-09-30
GB2015536.2A GB2600384A (en) 2020-09-30 2020-09-30 Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
PCT/EP2021/076811 WO2022069552A1 (en) 2020-09-30 2021-09-29 Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia

Publications (2)

Publication Number Publication Date
JP2023543993A true JP2023543993A (ja) 2023-10-19
JP2023543993A5 JP2023543993A5 (https=) 2024-10-04

Family

ID=73197201

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023519016A Pending JP2023543993A (ja) 2020-09-30 2021-09-29 遺伝性出血性毛細血管拡張症の治療における使用のためのアロステリックａｋｔ阻害剤

Country Status (13)

Country Link
US (1) US12466839B2 (https=)
EP (1) EP4221713A1 (https=)
JP (1) JP2023543993A (https=)
KR (1) KR20230080448A (https=)
CN (1) CN116419924A (https=)
AU (1) AU2021352108B2 (https=)
BR (1) BR112023004885A2 (https=)
CA (1) CA3192433A1 (https=)
CL (1) CL2023000926A1 (https=)
GB (1) GB2600384A (https=)
IL (1) IL301466A (https=)
MX (1) MX2023002996A (https=)
WO (1) WO2022069552A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
WO2026038045A1 (en) 2024-08-15 2026-02-19 Almac Discovery Limited Crystalline forms of 6-(4-((1s,3s)-1-amino-3-hydroxycyclobutyl)phenyl)-1-ethyl-7-phenyl-1h-pyrido[2,3-b][1,4]oxazin-2(3h)-one salts and free base

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013515710A (ja) * 2009-12-23 2013-05-09 アルマック・ディスカバリー・リミテッド Ａｋｔ活性の阻害剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI301760B (en) 2004-02-27 2008-10-11 Merz Pharma Gmbh & Co Kgaa Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
US7910561B2 (en) 2004-12-15 2011-03-22 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
EP1898903B8 (en) 2005-06-10 2013-05-15 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2008011032A1 (en) 2006-07-17 2008-01-24 Amgen Inc. Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
JP2010512312A (ja) 2006-12-06 2010-04-22 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性の阻害剤
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
JP2011522048A (ja) 2008-06-03 2011-07-28 メルク・シャープ・エンド・ドーム・コーポレイション Ａｋｔ活性の阻害剤
US8536193B2 (en) 2008-06-03 2013-09-17 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
EP2116237A1 (en) 2008-08-05 2009-11-11 Polichem SA Compositions for treating rosacea comprising chitosan and a dicarboxylic acid
EA201101186A1 (ru) 2009-02-13 2012-04-30 Байер Фарма Акциенгезельшафт Конденсированные пиримидины
HUE026323T2 (en) 2011-04-07 2016-05-30 Bayer Ip Gmbh Imidazopyridazines as akt kinase inhibitors
EP3294314A4 (en) 2015-05-15 2019-01-16 Memorial Sloan Kettering Cancer Center USE OF PHOPHOINOSITIDE-3-KINASE INHIBITORS FOR THE TREATMENT OF VASCULAR DISEASES
MX2020002611A (es) 2017-09-07 2020-07-13 Univ Res Inst Inc Augusta Activador especifico de akt3 y usos del mismo.
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013515710A (ja) * 2009-12-23 2013-05-09 アルマック・ディスカバリー・リミテッド Ａｋｔ活性の阻害剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANGIOGENESIS, vol. 18, JPN6025040597, 2015, pages 541, ISSN: 0005816558 *
CIRCULATION, vol. 138, no. 21, JPN6025040596, 20 November 2018 (2018-11-20), pages 2379 - 2394, ISSN: 0005816559 *

Also Published As

Publication number Publication date
US20240092801A1 (en) 2024-03-21
AU2021352108A1 (en) 2023-05-11
CN116419924A (zh) 2023-07-11
GB2600384A (en) 2022-05-04
WO2022069552A1 (en) 2022-04-07
CL2023000926A1 (es) 2023-11-03
EP4221713A1 (en) 2023-08-09
MX2023002996A (es) 2023-05-03
KR20230080448A (ko) 2023-06-07
CA3192433A1 (en) 2022-04-07
GB202015536D0 (en) 2020-11-11
AU2021352108B2 (en) 2026-04-02
US12466839B2 (en) 2025-11-11
BR112023004885A2 (pt) 2023-04-18
IL301466A (en) 2023-05-01
AU2021352108A9 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
KR20110022589A (ko) 혈관 내피 성장 인자 수용체에 대한 특이적 억제제
EP3749646B1 (en) Heteroaryl compounds as kinase inhibitor
JP2015520143A (ja) 癌を治療するためのｂｕｂ１阻害薬としての置換されているシクロアルケノピラゾール類
AU2006214190A1 (en) Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
WO2004112710A2 (en) COMPOSITIONS AND METHODS FOR INHIBITING TGF-ß
AU2005269974A1 (en) Quinazoline modulators of hepatocyte growth factor / c-Met activity for the treatment of cancer
JP6866381B2 (ja) 化合物
JP2016536311A (ja) ヘテロアリール置換ピラゾール類
JP2006502165A (ja) ピラゾロピリジンならびにその作製および使用方法
KR20110060901A (ko) Ｎａｄｐｈ 옥시다아제 억제제로서 피라졸로 피리딘 유도체
KR20130002317A (ko) Ｎａｄｐｈ 옥시다아제 억제제인 피라졸로 피페리딘 유도체
AU2019364631B2 (en) Crystal forms of an ALK2 inhibitor
CN103097381A (zh) 作为激酶抑制剂的1，8-萘啶物质
CN102617548A (zh) 作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用
TW201629059A (zh) 二氫吲哚啉酮衍生物
US12466839B2 (en) Allosteric AKT inhibitors for use in the treatment of Hereditary Hemorrhagic Telangiectasia
JP2017515845A (ja) カルボキサミド誘導体
JP7713972B2 (ja) 線維性疾患治療用医薬組成物
WO2014060763A1 (en) Compounds useful for treating ocular neovasculan
JP2021523108A (ja) 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Ｂｃｌファミリーアンタゴニストであるアシルホスホノアミダートおよびアシルベンジルアミン
EP4182311B1 (en) 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases
EA049324B1 (ru) Аллостерические ингибиторы akt для применения в лечении наследственной геморрагической телеангиэктазии
JPWO2008020606A1 (ja) 血管新生阻害剤
JP2006217801A (ja) ＴＧＦβ阻害活性を有する化合物の新規用途
EP4313294B1 (en) 3-substituted 1h-pyrrolo[2,3-b]pyridine as grk5 modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260316